References in periodicals archive ?
3-q27 Change % of patients Candidate genes Loss 50-78 RB1 Loss 50-67 CDKN1B, ETV6 Loss 50-66 CDKN2A, CDKN2B, MTAP Loss 50-55 NOTCH, TRAF2, CARD9 Loss 21-44 SMAD5, MSH3, MCC, APC Loss 33-36 CYP1A1 Loss 29 PTPN23 Loss 22-29 CDKN2D, PRKCSH Loss 22 TP53 Loss 21 MAD1L1 Loss 11-21 PARK2 Table 3: Summary of the most frequent genomic alterations in BPDCN.
Overexpression of cyclin-dependent kinase inhibitor 1 (WAF1) from the kinase inhibitor protein group and PAK-[gamma] (p21- activated kinase [gamma]), combined with overexpression of CDKN2D (p19-INK4D) and cell division protein kinase 3 (CDK3), denote a major derangement in the regulation of cell-cycle progression.